When you see a medicine name, record three things together: its active ingredient, its brand and its exact form. That combination gives you a useful starting point for finding the right label. “Semaglutide,” “Wegovy” and “tablet” answer different questions. A drug-class name such as GLP-1 receptor agonist is broader still. The examples below show how those layers fit together without choosing a treatment for you.
Separate the four layers
The active ingredient names the drug substance in the product. The brand is the marketed product name. The form and route describe how that product is supplied and given, such as an oral tablet or an injection under the skin. The drug class describes a category of activity: the cited semaglutide labels identify GLP-1 receptor agonist activity, while the tirzepatide labels identify both GIP and GLP-1 receptor agonist activity. [1] [4] [5] Keep these as separate fields in your notes instead of treating every name as a synonym.
An indication is another layer: the use described in a particular product’s label, with its patient group and conditions. Check it after matching the product identity. A shared ingredient or class does not tell you which formulation or labeled use someone is discussing. The Wegovy label, for example, has separate indication statements for injection and tablets. [1]
Use the label-linked naming map
| Label entry and class | Ingredient | Form | Source |
|---|---|---|---|
| Wegovy — GLP-1 receptor agonist | Semaglutide | Injection; tablets | [1] |
| Ozempic injection — GLP-1 receptor agonist | Semaglutide | Injection | [2] |
| Ozempic tablets / Rybelsus — GLP-1 receptor agonist | Semaglutide | Oral tablets | [3] |
| Zepbound — GIP and GLP-1 receptor agonist | Tirzepatide | Injection | [4] |
| Mounjaro — GIP and GLP-1 receptor agonist | Tirzepatide | Injection | [5] |
| Foundayo — GLP-1 receptor agonist | Orforglipron | Oral tablets | [6] |
These are selected U.S. label examples checked November 15, 2026, rather than an exhaustive list or a ranking. The source numbers open the corresponding label references. Read the full current entry for its indications, warnings and instructions; the table only helps identify which entry to open.
Notice what a brand name leaves out
The current Wegovy entry includes injection and oral tablets. Ozempic also needs its form specified: the injection has its own label entry, while another entry covers Ozempic tablets and Rybelsus tablets. [1] [2] [3] Writing only “Ozempic” in a comparison note leaves a question unanswered. Ask which product and form the person means before comparing its label with another medicine.
The oral semaglutide label explicitly says Rybelsus and Ozempic tablets are not substitutable milligram for milligram. [3] Use that as a reminder to bring product changes to the prescriber or pharmacist. This naming map supplies no conversion, switching schedule or instruction to replace one product with another.
A tablet is a form rather than an ingredient. Foundayo tablets contain orforglipron, while Wegovy tablets contain semaglutide. Both cited labels identify GLP-1 receptor agonist activity. [1] [6] A conversation about a “GLP-1 pill” therefore still needs the actual product name.
Work through one label lookup
Imagine you are organizing a question about Wegovy tablets. Open source 1, confirm that the heading includes tablets, and record semaglutide as the ingredient and oral use as the route. Then read the tablet-specific indication section. It includes weight reduction and long-term maintenance in adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. [1]
The injection section separately includes an obesity indication for patients aged 12 years and older; the tablet indication quoted above is for adults. [1] That difference shows why you should keep the form attached to the brand throughout the lookup. Record what the relevant section actually says and take questions about your situation to the clinician. A label lookup does not decide your eligibility.
Keep product approval separate from the ingredient name
A vial described with an ingredient name is not established as an FDA-approved branded product by that wording. FDA explains that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before marketing. [7] If a proposed product is compounded, ask the care team and dispensing pharmacy to identify it clearly rather than assigning it a brand from this table.
DailyMed is a useful place to locate company-submitted labeling, but its database also includes unapproved products. NLM explains that its in-use labeling can differ from the most recent FDA-approved labeling and points readers to Drugs@FDA for approved prescription labeling. [8] Keep the exact label URL and the date you checked it. If details conflict with the packaging or your care instructions, ask the pharmacist or prescriber to resolve the specific mismatch.
Explore a disclosed background resource
SHARED OWNERSHIP
Weight Loss & Nutrition and Peptide Dossier share ownership.
Read Peptide Dossier’s semaglutide background guide ↗For deeper background on semaglutide’s formulations and human research, the linked Peptide Dossier guide is additional editorial reading. The product identities in this naming map come from the independent label sources below. Keep the exact product label at hand when reading broader discussions of an ingredient.
Keep a private medicine-identity worksheet
Exact brand or product name: __________
Active ingredient: __________
Drug class shown in the label: __________
Form and route: __________
Exact label URL and date checked: __________
Relevant indication and patient group: __________
Unresolved mismatch or question: __________
Prescriber or pharmacist to ask: __________
Keep this worksheet privately with your own notes; it has no online input fields. After identifying the product, read the patient information or Medication Guide and the warnings that accompany it. Bring the unresolved question, along with the exact name and form, to the care team. That gives the next conversation a specific starting point.
Sources & further reading
- DailyMed, Wegovy injection and tablets
- DailyMed, Ozempic injection
- DailyMed, Ozempic tablets and Rybelsus tablets
- DailyMed, Zepbound
- DailyMed, Mounjaro
- DailyMed, Foundayo
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- National Library of Medicine, About DailyMed
Sources checked November 15, 2026. Examples and worksheets are original illustrations unless stated otherwise.
Have a correction or a source we should consider?
Contact the publication ↗